SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sheng-Shun Yang, Jia-Horng Kao, Asunaprevir-containing regimens for the treatment of hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2015, 9, 1, 9

    CrossRef

  2. 2
    K. Kosaka, M. Imamura, C. N. Hayes, H. Abe, N. Hiraga, S. Yoshimi, E. Murakami, T. Kawaoka, M. Tsuge, H. Aikata, D. Miki, H. Ochi, H. Matsui, A. Kanai, T. Inaba, K. Chayama, Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, Journal of Viral Hepatitis, 2015, 22, 1
  3. 3
    Kazuaki Chayama, Fukiko Mitsui, C Nelson Hayes, Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2015, 9, 1, 21

    CrossRef

  4. 4
    Saurabh (Rob) Aggarwal, A survey of breakthrough therapy designations, Nature Biotechnology, 2014, 32, 4, 323

    CrossRef

  5. You have free access to this content5
    Masaru Enomoto, Hiroyasu Morikawa, Yoshiki Murakami, Akihiro Tamori, Norifumi Kawada, Adjuvant epoetin-β with peginterferon-α and ribavirin in Japanese ribavirin-intolerant relapsed patients with chronic hepatitis C genotype 2, Hepatology Research, 2014, 44, 10
  6. 6
    Michael Manns, Stanislas Pol, Ira M Jacobson, Patrick Marcellin, Stuart C Gordon, Cheng-Yuan Peng, Ting-Tsung Chang, Gregory T Everson, Jeong Heo, Guido Gerken, Boris Yoffe, William J Towner, Marc Bourliere, Sophie Metivier, Chi-Jen Chu, William Sievert, Jean-Pierre Bronowicki, Dominique Thabut, Youn-Jae Lee, Jia-Horng Kao, Fiona McPhee, Justin Kopit, Patricia Mendez, Misti Linaberry, Eric Hughes, Stephanie Noviello, All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study, The Lancet, 2014, 384, 9954, 1597

    CrossRef

  7. 7
    Raewyn M. Poole, Daclatasvir + Asunaprevir: First Global Approval, Drugs, 2014, 74, 13, 1559

    CrossRef

  8. 8
    Hugh Adler, John S Lambert, Daclatasvir for the treatment of hepatitis C virus infection, Expert Review of Gastroenterology & Hepatology, 2014, 8, 7, 725

    CrossRef

  9. 9
    Hiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Akio Ido, Kazuhide Yamamoto, Koichi Takaguchi, Namiki Izumi, Kazuhiko Koike, Tetsuo Takehara, Norifumi Kawada, Michio Sata, Hidetaka Miyagoshi, Timothy Eley, Fiona McPhee, Andrew Damokosh, Hiroki Ishikawa, Eric Hughes, Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection, Hepatology, 2014, 59, 6
  10. You have free access to this content10
    Mika Miura, Shinya Maekawa, Mitsuaki Sato, Nobutoshi Komatsu, Akihisa Tatsumi, Shinichi Takano, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto, Nobuyuki Enomoto, Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection, Hepatology Research, 2014, 44, 14
  11. 11
    Warren N. Schmidt, David R. Nelson, Jean–Michel Pawlotsky, Kenneth E. Sherman, David L. Thomas, Raymond T. Chung, Direct-Acting Antiviral Agents and the Path to Interferon Independence, Clinical Gastroenterology and Hepatology, 2014, 12, 5, 728

    CrossRef

  12. 12
    Makonen Belema, Omar D. Lopez, John A. Bender, Jeffrey L. Romine, Denis R. St. Laurent, David R. Langley, Julie A. Lemm, Donald R. O’Boyle, Jin-Hua Sun, Chunfu Wang, Robert A. Fridell, Nicholas A. Meanwell, Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors, Journal of Medicinal Chemistry, 2014, 57, 5, 1643

    CrossRef

  13. 13
    Makonen Belema, Nicholas A. Meanwell, Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect, Journal of Medicinal Chemistry, 2014, 57, 12, 5057

    CrossRef

  14. 14
    Huiying Rao, Lai Wei, Juan Carlos Lopez-Talavera, Jia Shang, Hong Chen, Jun Li, Qing Xie, Zhiliang Gao, Lei Wang, Jia Wei, Jianning Jiang, Yongtao Sun, Ruifeng Yang, Hong Li, Haiying Zhang, Zuojiong Gong, Lunli Zhang, Longfeng Zhao, Xiaoguang Dou, Junqi Niu, Hong You, Zhi Chen, Qin Ning, Guozhong Gong, Shuhuan Wu, Wei Ji, Qing Mao, Hong Tang, Shuchen Li, Shaofeng Wei, Jian Sun, Jiaji Jiang, Lungen Lu, Jidong Jia, Hui Zhuang, Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection, Journal of Gastroenterology and Hepatology, 2014, 29, 3
  15. 15
    Gregory T. Everson, Karen D. Sims, Maribel Rodriguez-Torres, Christophe Hézode, Eric Lawitz, Marc Bourlière, Veronique Loustaud-Ratti, Vinod Rustgi, Howard Schwartz, Harvey Tatum, Patrick Marcellin, Stanislas Pol, Paul J. Thuluvath, Timothy Eley, Xiaodong Wang, Shu-Pang Huang, Fiona McPhee, Megan Wind-Rotolo, Ellen Chung, Claudio Pasquinelli, Dennis M. Grasela, David F. Gardiner, Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection, Gastroenterology, 2014, 146, 2, 420

    CrossRef

  16. 16
    Namiki Izumi, Efficacy of daclatasvir in hepatitis C virus, Expert Review of Anti-infective Therapy, 2014, 12, 9, 1025

    CrossRef

  17. 17
    C. Nelson Hayes, Kazuaki Chayama, Emerging treatments for chronic hepatitis C, Journal of the Formosan Medical Association, 2014,

    CrossRef

  18. 18
    Isabel Fofana, Nikolaus Jilg, Raymond T. Chung, Thomas F. Baumert, Entry inhibitors and future treatment of hepatitis C, Antiviral Research, 2014, 104, 136

    CrossRef

  19. 19
    T.R. Lim, B.H. Tan, D.J. Mutimer, Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection, International Journal of Antimicrobial Agents, 2014, 43, 1, 17

    CrossRef

  20. 20
    Norio Akuta, Fumitaka Suzuki, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Kenji Ikeda, Hiromitsu Kumada, Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b, Journal of Medical Virology, 2014, 86, 8
  21. 21
    Denis R. St. Laurent, Michael H. Serrano-Wu, Makonen Belema, Min Ding, Hua Fang, Min Gao, Jason T. Goodrich, Rudolph G. Krause, Julie A. Lemm, Mengping Liu, Omar D. Lopez, Van N. Nguyen, Peter T. Nower, Donald R. O’Boyle, Bradley C. Pearce, Jeffrey L. Romine, Lourdes Valera, Jin-Hua Sun, Ying-Kai Wang, Fukang Yang, Xuejie Yang, Nicholas A. Meanwell, Lawrence B. Snyder, HCV NS5A Replication Complex Inhibitors. Part 4.1 Optimization for Genotype 1a Replicon Inhibitory Activity, Journal of Medicinal Chemistry, 2014, 57, 5, 1976

    CrossRef

  22. 22
    Ed Gane, Hepatitis C beware—the end is nigh, The Lancet, 2014, 384, 9954, 1557

    CrossRef

  23. 23
    Makonen Belema, Van N. Nguyen, Carol Bachand, Dan H. Deon, Jason T. Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Jeffrey L. Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, Juliang Zhu, Henry S. Wong, David R. Langley, Stephen P. Adams, Glenn H. Cantor, Anjaneya Chimalakonda, Aberra Fura, Benjamin M. Johnson, Jay O. Knipe, Dawn D. Parker, Kenneth S. Santone, Robert A. Fridell, Julie A. Lemm, Donald R. O’Boyle, Richard J. Colonno, Min Gao, Nicholas A. Meanwell, Lawrence G. Hamann, Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir, Journal of Medicinal Chemistry, 2014, 57, 5, 2013

    CrossRef

  24. 24
    D. L. Wyles, J. A. Gutierrez, Importance of HCV genotype 1 subtypes for drug resistance and response to therapy, Journal of Viral Hepatitis, 2014, 21, 4
  25. 25
    H. Konishi, T. Motomura, Y. Matsumoto, N. Harimoto, T. Ikegami, T. Yoshizumi, Y. Soejima, K. Shirabe, T. Fukuhara, Y. Maehara, Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant, Journal of Viral Hepatitis, 2014, 21, 6
  26. 26
    Celia Perales, Nathan M Beach, Julie Sheldon, Esteban Domingo, Molecular basis of interferon resistance in hepatitis C virus, Current Opinion in Virology, 2014, 8, 38

    CrossRef

  27. 27
    Andres F Carrion, Julio Gutierrez, Paul Martin, New antiviral agents for the treatment of hepatitis C: ABT-450, Expert Opinion on Pharmacotherapy, 2014, 15, 5, 711

    CrossRef

  28. 28
    Sabela Lens, Ignacio Alfaro, Perspectivas futuras del tratamiento de la hepatitis C, ¿sin interferón y sin ribavirina?, Gastroenterología y Hepatología, 2014, 37, 5, 311

    CrossRef

  29. 29
    Susan Jenkins, Paul Scola, Fiona McPhee, Jay Knipe, Christoph Gesenberg, Michael Sinz, Vinod Arora, Gary Pilcher, Kenneth Santone, Preclinical Pharmacokinetics and In Vitro Metabolism of BMS-605339: A Novel HCV NS3 Protease Inhibitor, Journal of Pharmaceutical Sciences, 2014, 103, 6
  30. 30
    Naohiko Masaki, Masaya Sugiyama, Noritomo Shimada, Yasuhito Tanaka, Makoto Nakamuta, Namiki Izumi, Sumio Watanabe, Akihito Tsubota, Masafumi Komatsu, Tsutomu Masaki, Nobuyuki Enomoto, Masashi Yoneda, Kazumoto Murata, Kiyoaki Ito, Kazuhiko Koike, Masashi Mizokami, Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2014, 29, 12
  31. 31
    Anna S. Lok, David F. Gardiner, Christophe Hézode, Eric J. Lawitz, Marc Bourlière, Gregory T. Everson, Patrick Marcellin, Maribel Rodriguez-Torres, Stanislas Pol, Lawrence Serfaty, Timothy Eley, Shu-Pang Huang, Jianling Li, Megan Wind-Rotolo, Fei Yu, Fiona McPhee, Dennis M. Grasela, Claudio Pasquinelli, Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders, Journal of Hepatology, 2014, 60, 3, 490

    CrossRef

  32. 32
    Kentaro Matsuura, Tsunamasa Watanabe, Yasuhito Tanaka, Role of IL28B for chronic hepatitis C treatment toward personalized medicine, Journal of Gastroenterology and Hepatology, 2014, 29, 2
  33. 33
    Tetsuo Takehara, Simeprevir for the treatment of chronic hepatitis C genotype 1 infection, Expert Review of Anti-infective Therapy, 2014, 12, 8, 909

    CrossRef

  34. 34
    Eric Lawitz, Fred F Poordad, Phillip S Pang, Robert H Hyland, Xiao Ding, Hongmei Mo, William T Symonds, John G McHutchison, Fernando E Membreno, Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial, The Lancet, 2014, 383, 9916, 515

    CrossRef

  35. 35
    Tomokazu Kawaoka, Shoichi Takahashi, Yoshiiku Kawakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Hideyuki Hyogo, Hiroshi Aikata, Kohei Ishiyama, Hirotaka Tashiro, Hideki Ohdan, Junko Tanaka, Kazuaki Chayama, Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, Hepatology Research, 2014, 44, 14
  36. 36
    Paul M. Scola, Li-Qiang Sun, Alan Xiangdong Wang, Jie Chen, Ny Sin, Brian L. Venables, Sing-Yuen Sit, Yan Chen, Anthony Cocuzza, Donna M. Bilder, Stanley V. D’Andrea, Barbara Zheng, Piyasena Hewawasam, Yong Tu, Jacques Friborg, Paul Falk, Dennis Hernandez, Steven Levine, Chaoqun Chen, Fei Yu, Amy K. Sheaffer, Guangzhi Zhai, Diana Barry, Jay O. Knipe, Yong-Hae Han, Richard Schartman, Maria Donoso, Kathy Mosure, Michael W. Sinz, Tatyana Zvyaga, Andrew C. Good, Ramkumar Rajamani, Kevin Kish, Jeffrey Tredup, Herbert E. Klei, Qi Gao, Luciano Mueller, Richard J. Colonno, Dennis M. Grasela, Stephen P. Adams, James Loy, Paul C. Levesque, Huabin Sun, Hong Shi, Lucy Sun, William Warner, Danshi Li, Jialong Zhu, Nicholas A. Meanwell, Fiona McPhee, The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection, Journal of Medicinal Chemistry, 2014, 57, 5, 1730

    CrossRef

  37. 37
    Timothy Eley, Heather Sevinsky, Shu-Pang Huang, Bing He, Kurt Zhu, Hamza Kandoussi, David Gardiner, Dennis M. Grasela, Richard Bertz, Marc Bifano, The Pharmacokinetics of Daclatasvir and Asunaprevir Administered in Combination in Studies in Healthy Subjects and Patients Infected with Hepatitis C Virus, Clinical Drug Investigation, 2014, 34, 9, 661

    CrossRef

  38. 38
    Vincenza Conteduca, Domenico Sansonno, Sabino Russi, Fabio Pavone, Franco Dammacco, Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents, Journal of Infection, 2014, 68, 1, 1

    CrossRef

  39. 39
    Nobuhiro Aizawa, Hirayuki Enomoto, Tomoyuki Takashima, Yoshiyuki Sakai, Kazunari Iwata, Naoto Ikeda, Hironori Tanaka, Yoshinori Iwata, Masaki Saito, Hiroyasu Imanishi, Hiroko Iijima, Shuhei Nishiguchi, Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C, Journal of Gastroenterology, 2014, 49, 8, 1253

    CrossRef

  40. 40
    Kazuaki Chayama, Treatment of chronic hepatitis C recent development and future perspective, Kanzo, 2014, 55, 1, 8

    CrossRef

  41. 41
    Tomokazu Kawaoka, Shoichi Takahashi, Yumiko Tatsukawa, Akira Hiramatsu, Nobuhiko Hiraga, Daiki Miki, Masataka Tsuge, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Kouhei Ishiyama, Kentaro Ide, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama, Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, Hepatology Research, 2014, 44, 12
  42. 42
    Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Masanori Miyazaki, Sadaharu Iio, Masahide Oshita, Hideki Hagiwara, Eiji Mita, Yoshiaki Inui, Taizo Hijioka, Masami Inada, Shinji Tamura, Harumasa Yoshihara, Atsuo Inoue, Yasuharu Imai, Takuya Miyagi, Yuichi Yoshida, Tomohide Tatsumi, Tatsuya Kanto, Akinori Kasahara, Norio Hayashi, Tetsuo Takehara, Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1, Journal of Gastroenterology, 2014, 49, 4, 737

    CrossRef

  43. 43
    Donald R. O’Boyle, Peter T. Nower, Jin-Hua Sun, Robert Fridell, Chunfu Wang, Lourdes Valera, Min Gao, A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir, Journal of Virological Methods, 2013, 193, 1, 68

    CrossRef

  44. 44
    Erik De Clercq, A Cutting-Edge View on the Current State of Antiviral Drug Development, Medicinal Research Reviews, 2013, 33, 6
  45. You have free access to this content45
    Tsugiko Oze, Naoki Hiramatsu, Eiji Mita, Norio Akuta, Naoya Sakamoto, Hiroaki Nagano, Yoshito Itoh, Shuichi Kaneko, Namiki Izumi, Hideyuki Nomura, Norio Hayashi, Tetsuo Takehara, A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan, Hepatology Research, 2013, 43, 1
  46. 46
    Dinesh Jothimani, George M. Chandy, Hari Conjeevaram, A new era in the treatment of chronic hepatitis C infection, Indian Journal of Gastroenterology, 2013, 32, 2, 71

    CrossRef

  47. 47
    Hiromi Abe, C Nelson Hayes, Nobuhiko Hiraga, Michio Imamura, Masataka Tsuge, Daiki Miki, Shoichi Takahashi, Hidenori Ochi, Kazuaki Chayama, A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, The American Journal of Gastroenterology, 2013, 108, 9, 1464

    CrossRef

  48. 48
    Sonal Kumar, Ira Jacobson, All Oral HCV Therapies of the Future, Current Hepatitis Reports, 2013, 12, 4, 214

    CrossRef

  49. 49
    E. J. Lawitz, M. Rodriguez-Torres, J. Denning, A. Mathias, H. Mo, B. Gao, M. T. Cornpropst, M. M. Berrey, W. T. Symonds, All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR), Journal of Viral Hepatitis, 2013, 20, 10
  50. 50
    Jérôme Dumortier, Olivier Guillaud, Marie-Claude Gagnieu, Bénédicte Janbon, Laurent Juillard, Emmanuel Morelon, Vincent Leroy, Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: Is it feasible?, Journal of Clinical Virology, 2013, 56, 2, 146

    CrossRef

  51. 51
    Yoshiyasu Karino, Joji Toyota, Kenji Ikeda, Fumitaka Suzuki, Kazuaki Chayama, Yoshiiku Kawakami, Hiroki Ishikawa, Hideaki Watanabe, Dennis Hernandez, Fei Yu, Fiona McPhee, Hiromitsu Kumada, Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir, Journal of Hepatology, 2013, 58, 4, 646

    CrossRef

  52. 52
    Donald R. O'Boyle II, Jin-Hua Sun, Peter T. Nower, Julie A. Lemm, Robert A. Fridell, Chunfu Wang, Jeffrey L. Romine, Makonen Belema, Van N. Nguyen, Denis R. St. Laurent, Michael Serrano-Wu, Lawrence B. Snyder, Nicholas A. Meanwell, David R. Langley, Min Gao, Characterizations of HCV NS5A replication complex inhibitors, Virology, 2013, 444, 1-2, 343

    CrossRef

  53. 53
    N. Shi, N. Hiraga, M. Imamura, C. N. Hayes, Y. Zhang, K. Kosaka, A. Okazaki, E. Murakami, M. Tsuge, H. Abe, H. Aikata, S. Takahashi, H. Ochi, C. Tateno-Mukaidani, K. Yoshizato, H. Matsui, A. Kanai, T. Inaba, F. McPhee, M. Gao, K. Chayama, Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, Gut, 2013, 62, 7, 1055

    CrossRef

  54. You have free access to this content54
    C.-C. Hu, R.-N. Chien, Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C – authors’ reply, Alimentary Pharmacology & Therapeutics, 2013, 37, 4
  55. 55
    Sha Lou, Nicolas Cuniere, Bao-Ning Su, Lindsay A. Hobson, Concise asymmetric synthesis of a (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid-derived sulfonamide and ethyl ester, Organic & Biomolecular Chemistry, 2013, 11, 39, 6796

    CrossRef

  56. 56
    Joseph S. Doyle, Esther Aspinall, Danny Liew, Alexander J. Thompson, Margaret E. Hellard, Current and emerging antiviral treatments for hepatitis C infection, British Journal of Clinical Pharmacology, 2013, 75, 4
  57. 57
    T. Jake Liang, Marc G. Ghany, Current and Future Therapies for Hepatitis C Virus Infection, New England Journal of Medicine, 2013, 368, 20, 1907

    CrossRef

  58. 58
    Catherine AM Stedman, Current prospects for interferon-free treatment of hepatitis C in 2012, Journal of Gastroenterology and Hepatology, 2013, 28, 1
  59. 59
    Stanislas Pol, Daclatasvir, an efficient inhibitor of the hepatitis C virus replication complex protein NS5A: review of virologic data, treatment rationale and clinical trials, Clinical Investigation, 2013, 3, 2, 191

    CrossRef

  60. 60
    Erik De Clercq, Dancing with chemical formulae of antivirals: A panoramic view (Part 2), Biochemical Pharmacology, 2013, 86, 10, 1397

    CrossRef

  61. 61
    Jennifer J. Kiser, Charles Flexner, Direct-Acting Antiviral Agents for Hepatitis C Virus Infection, Annual Review of Pharmacology and Toxicology, 2013, 53, 1, 427

    CrossRef

  62. 62
    Yoshiyuki Suzuki, Kenji Ikeda, Fumitaka Suzuki, Joji Toyota, Yoshiyasu Karino, Kazuaki Chayama, Yoshiiku Kawakami, Hiroki Ishikawa, Hideaki Watanabe, Wenhua Hu, Timothy Eley, Fiona McPhee, Eric Hughes, Hiromitsu Kumada, Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options, Journal of Hepatology, 2013, 58, 4, 655

    CrossRef

  63. 63
    Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Chisa Kondo, Norio Itokawa, Ai Nakagawa, Satomi Hashimoto, Takeshi Fukuda, Yoko Matsushita, Hideko Kidokoro, Yoshiyuki Narahara, Katsuhisa Nakatsuka, Katsuhiko Iwakiri, Chiaki Kawamoto, Choitsu Sakamoto, Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study, Hepatitis Monthly, 2013, 13, 12

    CrossRef

  64. 64
    Arun B. Jesudian, Ype P. de Jong, Ira M. Jacobson, Emerging Therapeutic Targets for Hepatitis C Virus Infection, Clinical Gastroenterology and Hepatology, 2013, 11, 6, 612

    CrossRef

  65. You have free access to this content65
    Guidelines for the Management of Hepatitis C Virus Infection, Hepatology Research, 2013, 43, 1
  66. 66
    Anna Suk-Fong Lok, HCV NS5A Inhibitors in Development, Clinics in Liver Disease, 2013, 17, 1, 111

    CrossRef

  67. 67
    Makonen Belema, Van N. Nguyen, Denis R. St. Laurent, Omar D. Lopez, Yuping Qiu, Andrew C. Good, Peter T. Nower, Lourdes Valera, Donald R. O’Boyle, Jin-Hua Sun, Mengping Liu, Robert A. Fridell, Julie A. Lemm, Min Gao, Jay O. Knipe, Nicholas A. Meanwell, Lawrence B. Snyder, HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 15, 4428

    CrossRef

  68. 68
    Aaron Cohn, Andrew Aronsohn, HCV Therapy: Treat now or wait?, Current Hepatitis Reports, 2013, 12, 1, 7

    CrossRef

  69. 69
    Heiner Wedemeyer, Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 2, 76

    CrossRef

  70. 70
    J. González-Moreno, A. Payeras-Cifre, Hepatitis C Virus Infection: Looking for Interferon Free Regimens, The Scientific World Journal, 2013, 2013, 1

    CrossRef

  71. 71
    Kazi Abdus Salam, Nobuyoshi Akimitsu, Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives, BioMed Research International, 2013, 2013, 1

    CrossRef

  72. 72
    Chao Shi, Alexander Ploss, Hepatitis C virus vaccines in the era of new direct-acting antivirals, Expert Review of Gastroenterology & Hepatology, 2013, 7, 2, 171

    CrossRef

  73. 73
    Wan-Long Chuang, Ming-Lung Yu, Host factors determining the efficacy of hepatitis C treatment, Journal of Gastroenterology, 2013, 48, 1, 22

    CrossRef

  74. 74
    AnnMarie Liapakis, Joseph K. Lim, Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection, Hepatology, 2013, 58, 2
  75. 75
    Maria-Carlota Londoño, Sabela Lens, Xavier Forns, Interferon free regimens for the “difficult-to-treat”: Are we there?, Journal of Hepatology, 2013, 58, 4, 643

    CrossRef

  76. 76
    Sung Won Lee, Si Hyun Bae, Management of Hepatitis C Viral Infection Pre- and Post-liver Transplantation, The Journal of the Korean Society for Transplantation, 2013, 27, 1, 1

    CrossRef

  77. 77
    James R. Burton, Gregory T. Everson, Management of the Transplant Recipient with Chronic Hepatitis C, Clinics in Liver Disease, 2013, 17, 1, 73

    CrossRef

  78. 78
    Tatehiro Kagawa, Sei-ichiro Kojima, Koichi Shiraishi, Shunji Hirose, Yoshitaka Arase, Shinji Takashimizu, Norihito Watanabe, Naruhiko Nagata, Makoto Numata, Hirokazu Shiozawa, Yasuhiro Nishizaki, Mayu Toki, Teruji Sugita, Kijuro Nomura, Takashi Sakaguchi, Kazuhiro Atsukawa, Hiroto Tajima, Yoshihiro Tei, Tsutomu Inomoto, Tetsuya Mine, Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial, Hepatology Research, 2013, 43, 9
  79. 79
    Lai Wei, Hui-Ying Rao, Ye Wang, Ming Yang, Ying-Hui Gao, Molecular Epidemiology of HCV in Asia, Current Hepatitis Reports, 2013, 12, 3, 133

    CrossRef

  80. 80
    Michael P. Manns, Thomas von Hahn, Novel therapies for hepatitis C — one pill fits all?, Nature Reviews Drug Discovery, 2013, 12, 8, 595

    CrossRef

  81. 81
    D Alan Herbst, K Rajender Reddy, NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection, Expert Opinion on Investigational Drugs, 2013, 22, 10, 1337

    CrossRef

  82. 82
    Edward J. Gane, Catherine A. Stedman, Robert H. Hyland, Xiao Ding, Evguenia Svarovskaia, William T. Symonds, Robert G. Hindes, M. Michelle Berrey, Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C, New England Journal of Medicine, 2013, 368, 1, 34

    CrossRef

  83. 83
    Muhammad Anwar, Mazhar Iqbal, Mohammad S Yousef, Moazur Rahman, Over-expression and characterization of NS3 and NS5A of Hepatitis C virus genotype 3a, Microbial Cell Factories, 2013, 12, 1, 111

    CrossRef

  84. 84
    Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history, Expert Review of Anti-infective Therapy, 2013, 11, 5, 459

    CrossRef

  85. 85
    Miki Okano, Chiaki Okuse, Hiroshi Yotsuyanagi, Junko Shima, Nobuhiro Hattori, Ryuta Shigefuku, Yohei Noguchi, Moriaki Hatsugai, Kazunari Nakahara, Hiroki Ikeda, Hideaki Takahashi, Kotaro Matsunaga, Nobuyuki Matsumoto, Toshiya Ishii, Akira Sato, Yasunobu Fukuda, Kazuhiko Koike, Michihiro Suzuki, Fumio Itoh, Pegylated interferon and ribavirin combination therapy for chronic hepatitis C associated with thyroid dysfunction, Kanzo, 2013, 54, 11, 731

    CrossRef

  86. 86
    Christian M. Lange, Stefan Zeuzem, Perspectives and challenges of interferon-free therapy for chronic hepatitis C, Journal of Hepatology, 2013, 58, 3, 583

    CrossRef

  87. 87
    Takeshi Nishimura, Kanji Yamaguchi, Hideki Fujii, Yorihisa Okada, Chihiro Yokomizo, Toshihisa Niimi, Yoshio Sumida, Kohichiroh Yasui, Hironori Mitsuyoshi, Masahito Minami, Atsushi Umemura, Toshihide Shima, Takeshi Okanoue, Yoshito Itoh, Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study, Hepatology Research, 2013, 43, 5
  88. 88
    Maria-Carlota Londoño, Gonzalo Crespo, Xavier Forns, Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors, Current Opinion in Organ Transplantation, 2013, 18, 3, 271

    CrossRef

  89. 89
    Fiona McPhee, Dennis Hernandez, Fei Yu, Joseph Ueland, Aaron Monikowski, Arlene Carifa, Paul Falk, Chunfu Wang, Robert Fridell, Timothy Eley, Nannan Zhou, David Gardiner, Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir, Hepatology, 2013, 58, 3
  90. 90
    Yuichi Abe, Hussein Hassan Aly, Nobuhiko Hiraga, Michio Imamura, Takaji Wakita, Kunitada Shimotohno, Kazuaki Chayama, Makoto Hijikata, Thromboxane A2 Synthase Inhibitors Prevent Production of Infectious Hepatitis C Virus in Mice With Humanized Livers, Gastroenterology, 2013, 145, 3, 658

    CrossRef

  91. 91
    Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg, Geoffrey M. Dusheiko, Treatment decisions and contemporary versus pending treatments for hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 713

    CrossRef

  92. 92
    Kazuaki Chayama, C. Nelson Hayes, Waka Ohishi, Yoshiiku Kawakami, Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines, Journal of Gastroenterology, 2013, 48, 1, 1

    CrossRef

  93. 93
    Harry L.A. Janssen, Hendrik W. Reesink, Eric J. Lawitz, Stefan Zeuzem, Maribel Rodriguez-Torres, Keyur Patel, Adriaan J. van der Meer, Amy K. Patick, Alice Chen, Yi Zhou, Robert Persson, Barney D. King, Sakari Kauppinen, Arthur A. Levin, Michael R. Hodges, Treatment of HCV Infection by Targeting MicroRNA, New England Journal of Medicine, 2013, 368, 18, 1685

    CrossRef

  94. 94
    J. Toyota, I. Ozeki, Y. Karino, Y. Asahina, N. Izumi, S. Takahashi, Y. Kawakami, K. Chayama, N. Kamiya, K. Aoki, I. Yamada, Y. Suzuki, F. Suzuki, H. Kumada, Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b, Journal of Viral Hepatitis, 2013, 20, 3
  95. 95
    Andreas Geier, Was hat sich geändert? Was kommt demnächst?, MMW - Fortschritte der Medizin, 2013, 155, 19, 59

    CrossRef

  96. 96
    Stevan A Gonzalez, Emerging Therapeutic Options for Hepatitis C, 2013,

    CrossRef

  97. 97
    Kazuaki Chayama, C Nelson Hayes, Emerging Therapeutic Options for Hepatitis C, 2013,

    CrossRef

  98. 98
    Tarik Asselah, A revolution in HCV treatment with direct-acting antivirals: From non-response to eradication, Journal of Hepatology, 2012, 57, 2, 455

    CrossRef

  99. 99
    Jens Bukh, Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease, Gastroenterology, 2012, 142, 6, 1279

    CrossRef

  100. 100
    Robert J. Fontana, Eric A. Hughes, Henry Appelman, Robert Hindes, Dessislava Dimitrova, Marc Bifano, Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation, Liver Transplantation, 2012, 18, 9
  101. 101
    Stanislas Pol, Reem H Ghalib, Vinod K Rustgi, Claudia Martorell, Greg T Everson, Harvey A Tatum, Christophe Hézode, Joseph K Lim, Jean-Pierre Bronowicki, Gary A Abrams, Norbert Bräu, David W Morris, Paul J Thuluvath, Robert W Reindollar, Philip D Yin, Ulysses Diva, Robert Hindes, Fiona McPhee, Dennis Hernandez, Megan Wind-Rotolo, Eric A Hughes, Steven Schnittman, Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial, The Lancet Infectious Diseases, 2012, 12, 9, 671

    CrossRef

  102. 102
    Laurent Chatel-Chaix, Marie-Anne Germain, Matthias Götte, Daniel Lamarre, Direct-acting and host-targeting HCV inhibitors: current and future directions, Current Opinion in Virology, 2012, 2, 5, 588

    CrossRef

  103. 103
    Prakash Ramachandran, Peter C Hayes, Focusing on the patient: impact of new UK guidelines on treatment of chronic hepatitis C, Expert Review of Gastroenterology & Hepatology, 2012, 6, 3, 259

    CrossRef

  104. 104
    Denis R. St. Laurent, Makonen Belema, Min Gao, Jason Goodrich, Ramesh Kakarla, Jay O. Knipe, Julie A. Lemm, Mengping Liu, Omar D. Lopez, Van N. Nguyen, Peter T. Nower, Donald O’Boyle, Yuping Qiu, Jeffrey L. Romine, Michael H. Serrano-Wu, Jin-Hua Sun, Lourdes Valera, Fukang Yang, Xuejie Yang, Nicholas A. Meanwell, Lawrence B. Snyder, HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides, Bioorganic & Medicinal Chemistry Letters, 2012, 22, 19, 6063

    CrossRef

  105. You have full text access to this Open Access content105
    Daiki Miki, Hidenori Ochi, C. Nelson Hayes, Hiroshi Aikata, Kazuaki Chayama, Hepatocellular carcinoma: Towards personalized medicine, Cancer Science, 2012, 103, 5
  106. 106
    S. G. Chen Yi Mei, P. V. Desmond, A. J. Thompson, IL28B: Current and Future Use, Current Hepatitis Reports, 2012, 11, 3, 136

    CrossRef

  107. 107
    Maribel Rodríguez-Torres, Deana Hallman, Impact of Ethnicity and Race on Treatment Response: Past, Present and Future, Current Hepatitis Reports, 2012, 11, 3, 128

    CrossRef

  108. 108
    Mohamed A. Daw, Aghynya A. Dau, Mohamed M. Agnan, Influence of Healthcare-Associated Factors on the Efficacy of Hepatitis C Therapy, The Scientific World Journal, 2012, 2012, 1

    CrossRef

  109. 109
    AnnMarie Liapakis, Arun B Jesudian, Is there clinical utility toIL28Bgenotype testing in the treatment of chronic hepatitis C virus infection?, Pharmacogenomics, 2012, 13, 12, 1317

    CrossRef

  110. 110
    Libin Rong, Ruy M. Ribeiro, Alan S. Perelson, Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor, Bulletin of Mathematical Biology, 2012, 74, 8, 1789

    CrossRef

  111. 111
    Geoffrey W. McCaughan, New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting, Journal of Hepatology, 2012, 57, 6, 1361

    CrossRef

  112. 112
    Fernando E. Membreno, Eric J. Lawitz, Non-interferon Therapies for Hepatitis C, Current Hepatitis Reports, 2012, 11, 3, 146

    CrossRef

  113. 113
    Christopher O’Brien, Nicholas Agresti, NS5A Inhibitors, Current Hepatitis Reports, 2012, 11, 3, 181

    CrossRef

  114. 114
    Sylvie Deuffic–Burban, Pierre Deltenre, Maria Buti, Tommaso Stroffolini, Julie Parkes, Nikolai Mühlberger, Uwe Siebert, Christophe Moreno, Angelos Hatzakis, William Rosenberg, Stefan Zeuzem, Philippe Mathurin, Predicted Effects of Treatment for HCV Infection Vary Among European Countries, Gastroenterology, 2012, 143, 4, 974

    CrossRef

  115. 115
    Fumitaka Suzuki, Hitomi Sezaki, Norio Akuta, Yoshiyuki Suzuki, Yuya Seko, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saito, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Rie Mineta, Sachiyo Watahiki, Yuzo Miyakawa, Hiromitsu Kumada, Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b, Journal of Clinical Virology, 2012, 54, 4, 352

    CrossRef

  116. 116
    Brian L Pearlman, Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care, The Lancet Infectious Diseases, 2012, 12, 9, 717

    CrossRef

  117. 117
    Oscar Belda, Paul Targett-Adams, Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein, Virus Research, 2012, 170, 1-2, 1

    CrossRef

  118. 118
    Douglas Dieterich, The end of the beginning for hepatitis C treatment, Hepatology, 2012, 55, 3
  119. 119
    Erin T. Jenkins, Donald M. Jensen, The Importance of Rapid Viral Suppression in the Era of Directly Acting Antiviral Therapy for Hepatitis C Virus, Infectious Disease Clinics of North America, 2012, 26, 4, 879

    CrossRef

  120. 120
    Erik De Clercq, The race for interferon-free HCV therapies: a snapshot by the spring of 2012, Reviews in Medical Virology, 2012, 22, 6
  121. 121
    Joseph S. Doyle, Margaret E. Hellard, Alexander J. Thompson, The role of viral and host genetics in natural history and treatment of chronic HCV infection, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 413

    CrossRef

  122. 122
    Peter Ferenci, Treatment of chronic hepatitis C – are interferons really necessary?, Liver International, 2012, 32,
  123. 123
    Tarik Asselah, Triple therapy with boceprevir or telaprevir for prior HCV non-responders, Best Practice & Research Clinical Gastroenterology, 2012, 26, 4, 455

    CrossRef

  124. 124
    Gonzalo Crespo, Zoe Mariño, Miquel Navasa, Xavier Forns, Viral Hepatitis in Liver Transplantation, Gastroenterology, 2012, 142, 6, 1373

    CrossRef

  125. 125
    Nicholas A Shackel, When has the horse bolted?, Journal of Gastroenterology and Hepatology, 2012, 27, 7
  126. 126
    Robert Hamatake, Andrew Maynard, Wieslaw M. Kazmierski, Annual Reports in Medicinal Chemistry Volume 47, 2012,

    CrossRef

  127. 127
    Nicholas A. Meanwell, Stanley V. D'Andrea, Christopher W. Cianci, Ira B. Dicker, Kap-Sun Yeung, Makonen Belema, Mark Krystal, Antiviral Drug Discovery,
  128. 128
    Esperance Schaefer, Raymond T. Chung, Development of Anti-HCV Drugs,